Search ↗
Practical tools · 11 calculators · 6 quizzes

A little less guesswork.
A little more perspective.

Every tool shows its formula or scoring rule, states its assumptions, and cites the instrument or trial it rests on. The quizzes are the validated screens clinicians use, scored the published way, not made-up questionnaires.

Calculators

Numbers in, working shown.

+

Peptide dosage & reconstitution

Concentration after mixing, volume to draw, and the mark on a 100-unit syringe. Presets from every compound record.

Open ↗
+

Peptide cycle cost

How many vials a protocol needs and what it costs per week, per dose and in total.

Open ↗
+

TRT dose & injection volume

Turn a weekly testosterone dose into per-injection milligrams, millilitres and syringe units at your vial concentration.

Open ↗
+

Free & bioavailable testosterone

Calculated free testosterone from total T, SHBG and albumin using the Vermeulen equation.

Vermeulen et al., 1999 Open ↗
+

HOMA-IR insulin resistance

Insulin resistance index from fasting glucose and fasting insulin.

Matthews et al., 1985 Open ↗
+

BMI & GLP-1 eligibility

Your BMI, and whether it meets the FDA label criteria for prescription weight-loss medication.

FDA labeling criteria Open ↗
+

GLP-1 titration schedule

A dated dose-escalation calendar for semaglutide or tirzepatide from the label schedule.

FDA labels; STEP and SURMOUNT trials Open ↗
+

GLP-1 expected weight loss

What the pivotal trials reported on average, applied to your starting weight. An average, not a prediction.

STEP 1, SURMOUNT-1, SCALE trials Open ↗
+

Calories & macros

Maintenance calories from the Mifflin-St Jeor equation, with a protein-first macro split for cutting, maintaining or gaining.

Mifflin et al., 1990 Open ↗
+

Body fat, lean mass & FFMI

Body fat from tape measurements (US Navy method), lean mass, and fat-free mass index.

Hodgdon & Beckett, 1984 Open ↗
+

Annual care cost

Add consultations, labs, medication and follow-up to see the full-year picture.

Open ↗
Quizzes

The screens clinicians use.

Each one names its instrument and uses the published scoring. A result is a band, not a diagnosis.

Information with a human purpose

Clarity should feel
like a conversation.

A number or a score is the start of a better conversation with a clinician, not a substitute for one.

References

  1. Kosinski TM, Brown MC, Zavala PJ. Sterile Basics of Compounding: Relationship Between Syringe Size and Dosing Accuracy.Int J Pharm Compd 2018.PubMed 29385385
  2. Lau JL, Dunn MK. Therapeutic peptides: Historical perspectives, current development trends, and future directions.Bioorg Med Chem 2018.PubMed 28720325 · doi:10.1016/j.bmc.2017.06.052
  3. Wilson DM, Kiang TKL, Ensom MHH. Pharmacokinetics, safety, and patient acceptability of subcutaneous versus intramuscular testosterone injection for gender-affirming therapy: A pilot study.Am J Health Syst Pharm 2018.PubMed 29367424 · doi:10.2146/ajhp170160
  4. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum.J Clin Endocrinol Metab 1999.PubMed 10523012 · doi:10.1210/jcem.84.10.6079
  5. Tahapary DL, Pratisthita LB, Fitri NA, et al.. Challenges in the diagnosis of insulin resistance: Focusing on the role of HOMA-IR and Tryglyceride/glucose index.Diabetes Metab Syndr 2022.PubMed 35939943 · doi:10.1016/j.dsx.2022.102581
  6. Pedersen SD, Manjoo P, Dash S, et al.. Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update.CMAJ 2025.PubMed 40789597 · doi:10.1503/cmaj.250502
  7. Jastreboff AM, le Roux CW, Stefanski A, et al.. Tirzepatide for Obesity Treatment and Diabetes Prevention.N Engl J Med 2025.PubMed 39536238 · doi:10.1056/NEJMoa2410819
  8. Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide Once Weekly for the Treatment of Obesity.N Engl J Med 2022.PubMed 35658024 · doi:10.1056/NEJMoa2206038
  9. Mifflin MD, St Jeor ST, Hill LA, et al.. A new predictive equation for resting energy expenditure in healthy individuals.Am J Clin Nutr 1990.PubMed 2305711 · doi:10.1093/ajcn/51.2.241
  10. Jagim AR, Harty PS, Jones MT, et al.. Fat-Free Mass Index in Sport: Normative Profiles and Applications for Collegiate Athletes.J Strength Cond Res 2024.PubMed 39074219 · doi:10.1519/JSC.0000000000004864
  11. Zhdanava M, Ashton V, Korsiak J, et al.. Out-of-pocket costs for direct oral anticoagulants and prescription abandonment among patients with nonvalvular atrial fibrillation or venous thromboembolism.J Manag Care Spec Pharm 2025.PubMed 40152803 · doi:10.18553/jmcp.2025.31.4.366
  12. Morley JE, Perry HM 3rd. Androgen deficiency in aging men.Med Clin North Am 1999.PubMed 10503065 · doi:10.1016/s0025-7125(05)70163-2
  13. Rosen RC, Cappelleri JC, Smith MD, et al.. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction.Int J Impot Res 1999.PubMed 10637462 · doi:10.1038/sj.ijir.3900472
  14. Heinemann K, Ruebig A, Potthoff P, et al.. The Menopause Rating Scale (MRS) scale: a methodological review.Health Qual Life Outcomes 2004.PubMed 15345062 · doi:10.1186/1477-7525-2-45
  15. Morin CM, Belleville G, Bélanger L, et al.. The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response.Sleep 2011.PubMed 21532953 · doi:10.1093/sleep/34.5.601
  16. Elliott T, Yopes MC. Direct-to-Consumer Telemedicine.J Allergy Clin Immunol Pract 2019.PubMed 31706486 · doi:10.1016/j.jaip.2019.06.027
  17. Bhasin S, Brito JP, Cunningham GR, et al.. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.J Clin Endocrinol Metab 2018.PubMed 29562364 · doi:10.1210/jc.2018-00229

Literature retrieved from PubMed, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.